MA-ROCKET-SOFTWARE
1.5.2024 16:06:35 CEST | Business Wire | Press release
Rocket Software, Inc. (“Rocket Software”), a global technology leader in modernization software, has expanded upon its position as a partner of choice empowering the world's leading businesses on their modernization journeys. Closing the acquisition of the Application Modernization and Connectivity (AMC) business of OpenText, formerly part of Micro Focus, Rocket Software now offers customers modernization software solutions spanning the mainframe to the cloud. With a total purchase price of $2.275 billion, before taxes, fees and other adjustments, the deal increases the company’s revenue by over 60% and expands its customer base to more than 12,500 companies and network to more than 750 partners worldwide. In addition, the company welcomes more than 770 new software engineers, go-to-market professionals and other supporting team members and is hiring hundreds of additional Rocketeers to complement its existing team.
“Rocket Software’s customers are global market leaders that are constantly setting new benchmarks for excellence and innovation in their industries that we are proud to power and advance,” said Milan Shetti, president and CEO of Rocket Software. “The acquisition of the OpenText AMC business is a significant milestone that sets a similar new standard for modernization innovation and excellence at Rocket Software and greatly accelerates our strategic growth and market penetration. We now have the solutions, resources and expertise to tackle modernization challenges at scale, and the continued flexibility, winning culture, proven partnerships and growth mindset necessary to help our customers win today and well into the future.”
“The combination of OpenText’s AMC business and Rocket Software’s highly complementary businesses will create one of the world’s largest mainframe modernization and connectivity software companies,” said Peter Rutten, Research Vice-President, Performance Intensive Computing, IDC. “While many in the industry would champion moving everything to the cloud, or never moving anything off the mainframe, this investment shows Rocket Software’s commitment to meeting clients wherever they are in their modernization journey. Now Rocket Software will have a comprehensive portfolio that allows clients to modernize their workloads in place, move applications to the cloud or a combination of both through a hybrid strategy, which we see most enterprises prefer.”
With the added talent and innovation acquired from AMC, the company has set a new bar for modernization innovation in a single partner that:
- Offers Leading Technology for Mainframe Modernization by building on its deep expertise and long-standing commitment to optimizing mainframe environments to facilitate seamless, secure and compliant solutions that meet the demands of the digital era
- Meets Customers Wherever They Are on Their Journeys with an unyielding grasp of the entire landscape and comprehensive range of software solutions for any stage of modernization
- Values and Builds on Past and Current Investments by recognizing there is a better approach to the ‘rip and replace’ playbook for modernization and instead helps customers leverage their existing foundation for a seamless technological evolution
- Delivers Solutions as a True Partner, Not Just a Vendor with a 93.7% customer satisfaction rate for enterprises that demand nothing short of excellence, and need a trusted partner
Rocket Software will integrate and continue to develop AMC products to enhance its portfolio, helping customers stay competitive and leverage their data, applications and infrastructure regardless of their modernization strategy. In addition to several complementary Host Connectivity, Application Development and CORBA solutions, Rocket Software will also offer COBOL and Enterprise Suite, market leading technologies that allow companies the ability to run COBOL and PL/I applications on distributed or cloud servers. These added capabilities expand the mainframe modernization approaches that Rocket Software can deliver, enabling choice and allowing customers to run workloads wherever it makes sense for their business. This breadth, and the ability to integrate the various approaches, allows customers to seamlessly connect any combination of solutions across the modernization continuum.
“Application modernization is key to digital transformation in financial services,” said Martin Wildberger, EVP, Innovation & Technology, RBC. “As a Rocket Software customer, we've experienced firsthand the company’s commitment to innovation.”
“Within our organization, the need for modernization is a dynamic process, continually evolving as we grow and scale our business.," said José Fortemps, CTO, AG Insurance. "The OpenText AMC solutions have served us well and, now as part of Rocket Software, we look forward to exploring new opportunities for our data, application and infrastructure that propels us into the future.”
To learn more about Rocket Software and its enhanced capabilities and solutions, click here.
About Rocket Software
Rocket Software is the global technology leader in modernization and partner of choice that empowers the world's leading businesses on their modernization journeys, spanning core systems to the cloud. Trusted by over 12,500 customers and 750 partners, and with more than 3,000 global employees, Rocket Software enables customers to maximize their data, applications, and infrastructure to deliver critical services that power our modern world. Rocket Software is a privately held U.S. corporation headquartered in the Boston area with centers of excellence strategically located throughout North America, Europe, Asia and Australia. Rocket Software is a portfolio company of Bain Capital Private Equity. Follow Rocket Software on LinkedIn and Twitter or visit www.RocketSoftware.com.
Cautionary Information Regarding Forward-Looking Statements
Some of the statements contained in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements about our future performance, results and operations following the acquisition of the AMC business. These forward-looking statements are generally identified by the use of words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. These forward-looking statements reflect our views with respect to future events as of the date of this press release and are based on our current expectations, estimates, forecasts, projections, assumptions, beliefs and information. Although management believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that these expectations will prove to have been correct. All such forward-looking statements are subject to risks and uncertainties, many of which are outside of our control, and could cause future events or results to be materially different from those stated or implied in this press release. Such factors and risks include, but are not limited to, risks related to our ability to successfully integrate the AMC business and realize the expected synergies and certain other risks. It is not possible to predict or identify all such risks. We expressly disclaim any obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by applicable law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240430605619/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
